Xcout IntelGinkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., alongside its subsidiary entities, provides an advanced technological platform focused on the engineering of cells. This proprietary system is utilized to manipulate cellular functions, facilitating the biological creation of various products. These outputs span from innovative pharmaceutical treatments and vital food components to sustainable chemicals designed to replace those traditionally sourced from petroleum. The enterprise caters to a broad spectrum of industries, encompassing specialized chemical manufacturing, the agricultural sector, food production, consumer goods, and pharmaceuticals. Furthermore, Ginkgo Bioworks has forged a partnership with Selecta Biosciences, Inc., for the joint advancement of the ImmTOR technology platform. The company, founded in 2008, is headquartered in Boston, Massachusetts.
Subscribe to see Ginkgo Bioworks Holdings, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Ginkgo Bioworks Holdings, Inc. at a glance
Ginkgo Bioworks Holdings, Inc. is a biotech company headquartered in Boston, United States. It is publicly listed (DNA) with a market capitalisation of $835.7M. Xcout tracks 21 named people at Ginkgo Bioworks Holdings, Inc., including Jennifer Wipf (Co-Chief Operating Officer).
Ginkgo Bioworks Holdings, Inc. leadership
- Jennifer WipfCo-Chief Operating Officer
- Steven CoenChief Financial Officer
- Jason KellyCo-Founder, Co-COO, CEO & Director
- Reshma ShettyCo-Founder, President & Director
- Bartholomew CantonCo-Founder & CTO
- Austin CheCo-Founder & Head of Strategy
15 more named people on record for Ginkgo Bioworks Holdings, Inc., with roles, board committees and tenure — see the full roster →
Recent Ginkgo Bioworks Holdings, Inc. news
2 corporate events on record, with sources — see the full timeline →
Ginkgo Bioworks Holdings, Inc. competitors
A few of Ginkgo Bioworks Holdings, Inc.'s closest competitors — see the full list of competitors and alternatives →
Asimov, Inc. is an intelligent design and synthetic biology company headquartered in Boston, Massachusetts, offering tools and platforms for engineered biology.
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
ChainReactor Technologies provides infrastructure for industrial biology by combining physical AI, process engineering, and patented advanced manufacturing. The company offers modular benchtop bioreactors and a large biological model to help biomanufacturers predict cell behavior and test processes at scale before commercial production.
Emulate, Inc. (Emulate) is a biotechnology company that commercialized Organs-on-Chips technology—a human cell-based technology that recreates organ-level function to model organs in healthy and diseased states. The technology has applications in pharmaceutical research, product development, testing how different medicines, chemicals, and foods affect human health. Emulate has also worked with Cedars-Sinai Medical Center on a precision medicine initiative that uses Organs-on-Chips technology in the clinical setting. This initiative is designed to provide clinicians with better data about how a
CytoTronics is a biotechnology research company headquartered in Boston, Massachusetts, specializing in cell-based discovery and high-density electrode array technology.
iOrganBio is a biotechnology company founded in 2024 that develops AI-powered platforms for the precision engineering and manufacturing of human cells and organoids. The company's CellForge platform aims to create reproducible human cell models for research applications, including cardiac disease studies and biological simulation.
Get Ginkgo Bioworks Holdings, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Ginkgo Bioworks Holdings, Inc. in Xcout Intel
- 21 named people with titles, LinkedIn and board committees
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access